SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
BOULDER, Colo., Feb. 28, 2017 -- Miragen Therapeutics, Inc. (Nasdaq:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of microRNA-targeted therapies, today announced that William S. Marshall, Ph.D., President and Chief Executive Officer, will provide a company overview at the following conferences in March.
- Cowen and Company 37th Annual Health Care Conference
- Presentation Date: Tuesday, March 7, 2017
- Presentation Time: 8:40 a.m. ET
- Location: Boston Marriott Copley Place - Oppenheimer 27th Annual Healthcare Conference
- Presentation Date: Tuesday, March 21, 2017
- Presentation Time: 1:00 p.m. ET
- Location: Westin New York Grand Central
About Miragen Therapeutics, Inc.
Miragen Therapeutics, Inc. is a clinical-stage biopharmaceutical company discovering and developing proprietary RNA-targeted therapeutics with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. miRagen’s two lead product candidates, MRG-106 and MRG-201, are currently in Phase 1 clinical trials. miRagen’s clinical product candidate for the treatment of certain cancers, MRG-106, is an inhibitor of microRNA-155, which is found at abnormally high levels in several blood cancers. miRagen’s clinical product candidate for the treatment of pathological fibrosis, MRG-201, is a replacement for miR-29, which is found at abnormally low levels in a number of pathological fibrotic conditions, including cardiac, renal, hepatic, and pulmonary fibrosis, as well as systemic sclerosis. In addition to miRagen’s clinical programs, it is developing a pipeline of pre-clinical product candidates. The goal of miRagen’s translational medicine strategy is to progress rapidly to first in human studies once it has established the pharmacokinetics, pharmacodynamics and safety of the product candidate in pre-clinical studies. For more information, please visit www.miragentherapeutics.com.
For information on clinical trials please visit www.clinicaltrials.gov.
miRagen Investor Contact: Adam Levy Chief Business Officer (720) 407-4595 [email protected]
